A Study of LY3405105 in Participants With Advanced Cancer

Official Title

A Phase 1a/1b Study of LY3405105 Administered to Patients With Advanced Solid Tumours


The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts phase 1a and phase 1b. Participants will only enroll in one part.

Trial Description

Primary Outcome:

  • Number of Participants with Dose Limiting Toxicities (DLTs)
Secondary Outcome:
  • Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3405105
  • Objective Response Rate (ORR): Percentage of Participants with a Confirmed Complete Response (CR) or Partial Response (PR)
  • Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), Confirmed CR or PR
  • Duration of Response (DOR)
  • Time to Response (TTR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society